Universal alcohol/drug screening in prenatal care: a strategy for reducing racial disparities? Questioning the assumptions. by Roberts, Sarah CM & Nuru-Jeter, Amani
UCSF
UC San Francisco Previously Published Works
Title
Universal alcohol/drug screening in prenatal care: a strategy for reducing racial 
disparities? Questioning the assumptions.
Permalink
https://escholarship.org/uc/item/4qs371zb
Journal
Maternal and child health journal, 15(8)
ISSN
1092-7875
Authors
Roberts, Sarah CM
Nuru-Jeter, Amani
Publication Date
2011-11-01
DOI
10.1007/s10995-010-0720-6
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
COMMENTARY
Universal Alcohol/Drug Screening in Prenatal Care: A Strategy
for Reducing Racial Disparities? Questioning the Assumptions
Sarah C. M. Roberts • Amani Nuru-Jeter
Published online: 25 November 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Agencies and organizations promoting uni-
versal screening for alcohol and drug use in prenatal care
argue that universal screening will reduce White versus
Black racial disparities in reporting to Child Protective
Services (CPS) at delivery. Yet, no published research has
assessed the impact of universal screening on reporting
disparities or explored plausible mechanisms. This review
defines two potential mechanisms: Equitable Surveillance
and Effective Treatment and identifies assumptions under-
lying each mechanism. It reviews published literature
relating to each assumption. Research relating to assump-
tions underlying each mechanism is primarily inconclusive
or contradictory. Thus, available research does not support
the claim that universal screening for alcohol and drug use
in prenatal care reduces racial disparities in CPS reporting
at delivery. Reducing these reporting disparities requires
more than universal screening.
Keywords Screening  Pregnancy  Substance-related
disorders  Disparities  Child Welfare
Introduction
Government agencies and professional organizations
encourage prenatal health care providers to implement
universal screening for alcohol and drug use in prenatal
care [1–4]. Some agencies/organizations promoting uni-
versal screening argue that universal screening will reduce
Black-White racial disparities in reporting to Child Pro-
tective Services (CPS) at delivery [5–7]. Importantly, no
published research has assessed the impact of universal
screening on CPS reporting disparities at delivery or
explored the mechanisms through which universal screen-
ing could reduce these disparities. Understanding the
impact of universal screening on CPS reporting disparities
as well as the potential mechanisms through which uni-
versal screening could influence the disparities is essential
as many providers begin to implement universal screening.
Understanding these possible mechanisms requires a
look at screening in context of the larger system, which
includes the policies and practices of providers, women,
and institutions. Important points in this system are shown
in Fig. 1.
Two potential mechanisms have been alluded to in
discourse around universal screening. The first will be
referred to as: Equitable Surveillance. The second will be
referred to as: Effective Treatment.
Equitable Surveillance: Without explicitly stating the
logic connecting universal screening to CPS reporting
disparities, those arguing that universal screening will
reduce disparities [5, 7] often cite the Pinellas County
study [6]. In this study, Chasnoff et al. found that although
White and Black pregnant women used alcohol and drugs
at similar rates at their first prenatal care visit, Black
women were 10 times more likely than White women to be
reported to health authorities at delivery. In the discussion,
the authors speculate that reporting disparities exist
because prenatal providers primarily screen, and thus pri-
marily identify, Black women. Chasnoff has since pro-
posed universal screening as a solution to these reporting
disparities [7]. The logic appears to be that universal
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screening will lead providers to identify more alcohol and
drug use among White women during prenatal care. It
follows that identifying more White women as using
alcohol and drugs in prenatal care will lead providers to
report more White women to CPS at delivery, thereby
reducing reporting disparities. The argument is essentially
that screening for alcohol and drug use in prenatal care
functions as surveillance for CPS reporting at delivery.
Thus, the goal of universal screening is to create more
equitable surveillance where White women are just as
likely to be screened and therefore reported as Black
women.
Effective Treatment: Others suggest that universal
screening helps identify pregnant women needing treat-
ment earlier in pregnancy and ensures they receive needed
treatment, either Brief Interventions (BI) or formal treat-
ment [5, 8]. Although unstated in the published literature,
the premise underlying this argument is that providing
effective treatment during the prenatal period reduces the
need for and risk of CPS reporting at delivery. Reducing
the number of women (including Black women) identified
in prenatal care who continue to use alcohol and/or drugs
through delivery will reduce the number of Black women
reported at delivery, thereby reducing reporting disparities.
In addition to different perspectives on the role of
screening in reducing reporting disparities, the assump-
tions underlying these two mechanisms differ. Equitable
Surveillance assumes that: (1) prenatal providers screen
fewer White than Black women; [6, 9] (2) White and Black
women do not differ in patterns of alcohol and drug use
during the prenatal period; [6] (3) rates of identification at
delivery are disproportional to rates of use at delivery; and
(4) once providers identify pregnant women as using
alcohol and/or drugs, they are equally likely to report
White and Black women. Effective Treatment assumes that:
(1) women identified through screening in prenatal care
receive treatment; (2) there are no racial disparities in
treatment receipt; (3) treatment provided to women iden-
tified through universal screening in prenatal care is
effective; and (4) there are no racial disparities in treatment
effectiveness.
Methods
This paper examines the plausibility of the Equitable
Surveillance and Effective Treatment mechanisms by
reviewing published literature related to each assumption
outlined above. This review includes studies that relate to
each of the specified assumptions relating to racial distri-
bution of alcohol and drug use during pregnancy, screening
for alcohol and drug use during prenatal care and at
delivery, and brief interventions and treatment provided to
women who have alcohol and/or drug use identified
through universal screening in prenatal care. All included
studies were published through June 2009 in English-
language peer-reviewed journals. The one exception is the
case of Equitable Surveillance Assumption 4, where dis-
parities in a case that made it to the US Supreme Court are
described. In addition to studies known to the authors
through previous work on this subject, PubMed and Web of
Science were searched to identify all additional relevant
studies. Search terms included: ‘‘alcohol,’’ ‘‘substance
abuse,’’ ‘‘cocaine,’’ ‘‘methamphetamine,’’ ‘‘marijuana,’’
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Fig. 1 Universal screening in prenatal care in context
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‘‘heroin,’’ ‘‘ecstasy,’’ ‘‘illicit drugs,’’ ‘‘pregnancy,’’ ‘‘race,’’
‘‘screening,’’ and ‘‘brief intervention.’’ The resulting
abstracts were examined to identify studies that addressed
the assumptions outlined above. In addition to the keyword
searches, we searched the reference sections of identified
papers to find additional studies. We also used Web of
Science and Google Scholar to find additional studies that
had cited the studies we identified.
All studies we found that directly addressed the
assumptions were included. For assumptions where few to
no studies were identified, related studies were included
and limitations to relevance described. The part of Equi-
table Surveillance Assumption 3 that relates to racial dif-
ferences in use at delivery and in reduction and cessation
over the course of pregnancy is the only part of this review
in which there is a substantial body of research. For this
portion of the review, studies that compared White and
Black women directly with sufficient ‘‘n’’ to detect dif-
ferences, studies based in the United States, studies that
measured alcohol use and drug use as separate variables,
studies that were based on an entire population or sub-
population as well as prenatal clinic samples (including
cohorts) were included. Studies where people were inclu-
ded or excluded based on potential confounders, such as
those examining populations of women hospitalized for
injuries during pregnancy and those excluding women with
documented history of alcohol or drug abuse in medical
charts, were excluded.
Given the limited research on the topic, and evidence
available in non-peer reviewed outlets such as cases making
it to the Supreme Court, we conducted as exhaustive a review
as possible without restricting ourselves to specific inclu-
sion/exclusion criteria. Therefore, this paper presents a non-
systematic, yet comprehensive review of the literature rela-
ted to the assumptions underlying the Equitable Surveillance
and Effective Treatment mechanisms outlined above.
Findings
Equitable Surveillance
ES Assumption 1: Prenatal Providers Screen Fewer White
than Black Women: INCONCLUSIVE
No published studies directly address this question. We
found two published studies relevant to whether providers
screen fewer White than Black women during prenatal
care. In a review of medical charts of women delivering at
a university hospital, Kerker et al. [10] found that in some,
but not all, prenatal clinics, prenatal care providers were
less likely to document substance abuse history in charts of
White versus Black women. In a study of provider beliefs
about the prevalence of alcohol and drug use by race
among adolescents in their care, Teagle and Brindis found
that providers underestimated marijuana use among White
and alcohol use among Black adolescents [11]. Assuming
that provider beliefs about population distribution of
alcohol and drug use predict which women they screen,
providers would underscreen White women for marijuana
and Black women for alcohol. In addition, some have
suggested that public providers, who serve a higher pro-
portion of Black women [12], are more likely to screen
than private providers [6, 13]. However, while screening
practices appear to vary across institutions [10, 14], it is not
clear that public providers are more likely than private
providers to screen [1, 15, 16]. More research is needed to
better understand racial disparities in provider screening
practices. Research related to Assumption1 is inconclusive.
ES Assumption 2: White and Black Women Do Not Differ
in Patterns of Alcohol and Drug Use During the Prenatal
Period: NOT SUPPORTED
Both White and Black women use alcohol and drugs during
pregnancy. However, women differ with respect to both
substance and pattern of use. Most [17–24], but not all [6,
25, 26], studies have found that White women are more
likely than Black women to use any alcohol during preg-
nancy. Some [20, 25, 27, 28], but not all [17, 24, 29],
studies have found that racial differences disappear for
binge and heavy alcohol use. Published research about
whether White or Black women are more likely to use any
drug during pregnancy is inconclusive [6, 19, 21, 23, 30].
However, studies consistently find White women more
likely than Black women to use marijuana [6, 18, 30, 31]
and, with one exception [18], less likely to use cocaine [6,
22, 30] and either less [21] or just as likely [18] to have
heavier or more frequent drug use during pregnancy. In
addition, one study found that while White women were
more likely than Black women to use any alcohol, tobacco,
or drugs during pregnancy, they were less likely than Black
women to use two or three substances during pregnancy
[32]. Therefore, it appears that White and Black women
have similar rates of any use during the prenatal period.
However, substances and possibly patterns differ. Further
research is needed to better understand patterns of alcohol
and drug use during pregnancy among White and Black
women. Assumption 2 is not supported.
ES Assumption 3: Rates of Identification at Delivery
are Disproportional to Rates of Use at Delivery:
NOT SUPPORTED
Identification at delivery: Similar to prenatal care, some
have suggested that racial disparities in urine toxicology
Matern Child Health J (2011) 15:1127–1134 1129
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testing at delivery are due to more testing in public than
private hospitals [13, 33]. Urine testing practices at deliv-
ery do appear to vary across hospitals [34]. However,
variation is more complicated than differential testing in
public versus private hospitals. A recent study found sig-
nificant variation across hospitals in protocols providing
guidance for identifying use at delivery [35]. Hospitals
serving White and affluent patients had more detailed
protocols specifying the need for maternal consent or dis-
cussion prior to testing. Hospitals serving more Black and
lower-income women had less structured protocols [35].
Thus, providers at hospitals serving Black and low-income
patients may have more discretion about who to test at
delivery. There also may be differences within hospitals
both with respect to insurance-type and race. A study based
on interviews with nurse administrators at different hos-
pitals found that some hospitals use insurance status
(public insurance or self-pay) as a criterion to determine
which women to test [36]. Kerker et al. [37] found that
providers at a hospital serving low-income patients tested
White women for cocaine at delivery less than they tested
Black women. Similarly, Kunins et al. found that, among
women delivering at an urban hospital, White and other
women were less likely than Black women to be tested for
drugs [38]. Thus, providers may test fewer White than
Black women at delivery.
Rates of use at delivery: Kunins et al. also found that
racial differences in testing at delivery were proportional to
underlying differences in drug use at delivery [38]. A study
by Vega et al. supports this finding, showing White women
significantly less likely than Black women to have recently
used either alcohol or drugs at delivery [39]. This finding
differs from findings that measure alcohol and drug use at
first prenatal visit [6], at any time since knowledge of
pregnancy [17, 19–22, 24, 29], or as use within the past
month [18, 25, 27, 28, 40], which find that White women
are more likely or just as likely to use alcohol and drugs.
Other, but not all [41], studies at delivery have found
patterns similar to Vega and Kunins for drugs [42], espe-
cially cocaine [41, 43–48]. Findings about marijuana are
mixed [44, 46, 49].
It is possible that there are racial differences in reduction
or cessation of alcohol and drug use during pregnancy. In
general, pregnant women are less likely than non-pregnant
women to use alcohol and drugs (see [18, 19]) and women
tend to reduce use between the first and third trimesters
[24, 30], although this may not apply to cocaine [30].
However, evidence is mixed as to whether White and
Black women are similarly likely to reduce or cease
alcohol use once pregnant. Some studies find that White
and Black women are similarly likely to reduce or cease
use once pregnant [18, 19, 50, 51], while other studies find
that White women are more likely than Black women to
reduce use [25, 52–54],1 and one study found that White
women are less likely than Black women to reduce use
[55].2 Evidence is more consistent for heavier drinkers.
While White women are more likely than Black women to
binge drink outside of pregnancy, White and Black women
tend to have similar rates of binge drinking during preg-
nancy [25, 27, 28, 51]. This suggests that among women
who binge drink, White women may be more likely than
Black women to stop during pregnancy. Additionally, one
study found that among heavy drinkers, White and Black
women were equally likely to quit, but White women were
more likely to reduce their use [51]. Some studies find that
White and Black women are equally likely to cease mari-
juana, cocaine, and drug use in general [18, 19]; however,
other studies find that White women are more likely than
Black women to cease use [18, 50, 53] (See footnote 1).
Therefore, it is possible that White women may be less
likely than Black women to still be using drugs at delivery.
Thus, part of what appears to be disproportionate testing at
delivery may be testing proportionate to underlying dif-
ferences in rates of use at delivery. Therefore, Assumption
3 is not supported.
ES Assumption 4: Once Providers Identify Pregnant
Women as Using Alcohol and/or Drugs, They are
Equally Likely to Report White and Black Women:
NOT SUPPORTED
Findings from the Pinellas County study [6], described
above, suggest that White women are less likely than Black
women to be reported for alcohol and drug use at delivery.
In the Pinellas County study, Chasnoff et al. found that
White and Black women used alcohol and drugs at similar
rates at their first prenatal visits, although White women
were more likely than Black women to use marijuana and
less likely to use cocaine. However, at delivery Black
women were 10 times more likely than White women to be
reported to health authorities [6].
Under a policy at the Medical University of South
Carolina (MUSC) from 1989 to 1994 that was ruled
unconstitutional by the US Supreme Court, prenatal pro-
viders informed pregnant women who tested positive for
cocaine that they were required to get treatment, and if they
missed a treatment appointment or had a second positive
test, they would be reported to law enforcement and
prosecuted [13, 56]. Forty-one women were prose-
cuted under this policy; 40 of the 41 were Black [57].
Other women, mostly White, tested positive for
1 Hanna et al. (1994) does not report statistical significance levels,
but the trends in this study with large sample size are in this direction.
2 Prager et al. (1984) does not report statistical significance levels,
but the trend in this study with a large sample size is in this direction.
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methamphetamine and heroin, but were not reported to law
enforcement [58]. Both the Pinellas County study and the
MUSC prosecutions raise the possibility that disparities
may reflect differential response to cocaine versus alcohol
and other drugs [13].
While not directly about reporting disparities, studies
about disparities in responses to CPS reports are consistent
with studies about the initial reports. In a study of deter-
minants of discharge custody decisions for a cohort of
cocaine exposed newborns [59], Neuspiel et al. found that
among women identified as using cocaine while pregnant,
Black women were less likely than other women to have
custody of their newborns at discharge. Similarly, Mac-
Mahon found that among women whose healthy babies
tested positive for drugs, White women reported at delivery
were less likely than Black women to never regain custody
[60]. There does not appear to be research on disparities in
reporting due to alcohol.
Research about reporting at delivery indicates that pro-
viders are less likely to report White than Black women.
This appears due both to focus on cocaine and less
reporting of White than Black women using the same
substance. Assumption 4 is not supported.
Effective Treatment
ET Assumption 1: Women Identified Through Universal
Screening in Prenatal Care Receive Treatment:
PARTIALLY SUPPORTED
We found three studies that reported the percentage of
women identified through universal screening in prenatal
care who received either a BI or formal treatment. Kennedy
et al. [61] found that 77% of women identified through uni-
versal screening in prenatal care in Massachusetts received a
BI. Similarly, in Kaiser’s Early Start program, about 70% of
women who screened positive received at least one treatment
visit [62]. Messer et al. [63] found that one-half (51%) of
low-income women identified through universal screening
accepted treatment. Thus, while many who have alcohol and
drug use identified through universal screening in prenatal
care receive BIs or treatment, it appears that a large pro-
portion of women identified through universal screening
(23–49%) receiving neither a BI nor more formal treatment.
Assumption 1 is partially supported. However, research is
needed to understand the consequences of screening for
those who do not receive either a BI or treatment.
ET Assumption 2: There are No Racial Disparities
in Treatment Receipt: INCONCLUSIVE
Kogan et al. [64] used the 1988 National Maternal and Infant
Health Survey to examine racial differences in provider
advice about alcohol and drug use during pregnancy. They
found that White women were more likely than Black
women to have received advice about alcohol and just as
likely to have received advice about drugs [64]. In a study of
low-income pregnant women who used alcohol, O’Connor
and Whaley [65] found that White women were less likely
than Black women to have received advice about alcohol use
during pregnancy. Messer et al. [63] also examined a sample
of low-income women and found White women less likely
than Black women who needed treatment to accept treat-
ment. The different findings suggest that racial differences in
treatment receipt may vary by socioeconomic position.
Evidence related to Assumption 2 is inconclusive.
ET Assumption 3: Treatment Provided to Women Identified
Through Universal Screening in Prenatal Care is Effective:
INCONCLUSIVE
There is limited research about the effectiveness of BIs and
treatment provided to women identified through universal
screening in prenatal care. In a systematic review, the
United States Preventive Services Task Force (USPSTF)
concluded that screening and BIs for alcohol are effective
in general, but that studies during pregnancy were incon-
clusive [66]. A Cochrane review concluded that research
about effectiveness of screening and BIs for alcohol for
women in general was inconclusive [67]. Even less
research has been conducted about effectiveness for drugs.
The USPSTF concluded that it is not possible to determine
from published research whether BIs and treatment pro-
vided to people whose drug use is identified through uni-
versal screening in primary care are effective, including
during pregnancy [68]. Additional studies about effec-
tiveness of screening and BIs during pregnancy have found
mixed results, although more recent studies do seem to
suggest that it may be effective [15, 69–72]. However, the
Kaiser Permanente studies [15, 72] that include both
alcohol and drugs focus only on birth outcomes. As the
authors of these studies state, it is not known if the
improvements in outcomes were attributable to women’s
reductions in use [72]. Thus, screening and BIs may be
effective for alcohol, but the lack of research makes it
impossible to determine for drugs. Assumption 3 is sup-
ported for alcohol use. Research relating to assumption 3
for drug use is inconclusive.
ET Assumption 4: There are No Racial Disparities
in Treatment Effectiveness: NO EVIDENCE
There is no research about racial disparities in effectiveness
of treatment provided to pregnant women as a result of
identification through universal screening in prenatal care.
Thus, Assumption 4 is not supported.
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Conclusion
Research relating to assumptions underlying both Equita-
ble Surveillance and Effective Treatment is either incon-
clusive or contradictory. Available research does not
support the claim that universal screening for alcohol and
drug use in prenatal care will reduce racial disparities in
CPS reporting at delivery. Research indicates that there are
disparities at multiple points in this system, mainly in
testing and reporting at delivery. These disparities may
reflect more aggressive reporting of cocaine use [13] as
well as less reporting of White than Black women who use
the same substance. Research also suggests that a portion
of what appears to be biases in responses may actually be
proportional responses to underlying racial differences in
rates of alcohol and drug use, especially at delivery. Thus,
research contradicts most assumptions underlying Equita-
ble Surveillance.
The source of reporting disparities does not appear to be
bias in screening in prenatal care, but rather disparities in
responses and solutions to pregnant women’s alcohol and
drug use. Logically, Effective Treatment makes more sense
than Equitable Surveillance, because it accounts for the
possibility that White women may be less likely than Black
women to still be using drugs that put them at risk for CPS
reporting at delivery. The main problem with Effective
Treatment is the limited evidence that universal screening
leads to treatment and that treatment provided as a result of
identification in prenatal care is effective, especially for
drugs. There has been no research to date on racial dis-
parities in effectiveness of BIs and treatment provided as a
result of universal screening in prenatal care. However, it
seems unlikely that universal approaches such as universal
screening and brief interventions will reduce disparities
because reducing disparities generally requires specific
attention to ensuring that interventions are effective for the
group bearing disproportionate burden [73–75].
To make the Effective Treatment mechanism more
likely to reduce racial disparities in reporting, researchers
and practitioners need to develop, implement, and evaluate
interventions and ensure that they meet the needs of Black
women. Because screening for drug use in prenatal care
may function as surveillance for women for whom inter-
ventions are ineffective (or not accepted), researchers and
practitioners should be aware that efforts that identify
women for whom the interventions are ineffective could
place women under surveillance for CPS reporting. The
perception that screening for drug use leads to CPS
reporting is a reason that some women who use alcohol and
drugs physically avoid and emotionally disengage from
prenatal care [76] and, thus, is important to take into
account. Developing and implementing such interventions
that meet the needs of Black women will require a specific
commitment on the part of policy-makers to reduce dis-
parities [75]. It is unlikely to be accomplished as a side
goal of universal screening.
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